Background: The purpose of this study is to evaluate the clinical efficacy and safety of abraxane-based chemotherapy with/without nedaplatin in elderly patients with non-small-cell lung cancer (NSCLC). Materials an...Background: The purpose of this study is to evaluate the clinical efficacy and safety of abraxane-based chemotherapy with/without nedaplatin in elderly patients with non-small-cell lung cancer (NSCLC). Materials and methods: From October 2009 to January 2013, 48 elderly patients (≥65 years) with NSCLC were investigated in this clinical trial. The patients were randomized and equally allocated into arms A and AP- (A) abraxane (130 mg/m2, days 1, 8); (B) abraxane + nedaplatin (20 mg/m2 days 1-3, q3w). The parameters of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and side effects were evaluated between two arms. Results: Over 80% of the patients completed four cycles of chemotherapy. The total ORR was 21.3 %, DCR was 55.3%, PFS 4.5 months and OS 12.6 months. No significant difference was found between arms A and AP in terms of ORR (16.7% vs. 26.1%, P=0.665) or DCR (55.3% vs. 56.5%, P=0.871). The median PFS in arm A was 3.3 months [25-75% confidence interval (CI): 3.1-7.2] and 5.5 months (25-75% CI: 3.2-7.0) in arm AP with no statistical significance (P=0.640). The median OS in arm A was 12.6 months (25-75% CI: 5.7-26.2) and 15.1 months (25-75% CI: 6.4-35.3) in arm AP with no statistical significance (P=0.770). The side effects were mainly grade 1-2. The incidence of grade 3-4 toxicities was 29.1% in arm A and 62.5% in arm AP with a statistical significance (P=0.020). Conclusions: Compared with combined therapy, abraxane alone chemotherapy was beneficial for elderly NSCLC patients with better tolerability and less adverse events, whereas did not significantly differ in terms of ORR, DCR, PFS or OS.展开更多
目的探讨益气消癥汤治疗晚期非小细胞肺癌(Non-small-cell carcinoma,NSCLC)合并慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)的临床疗效。方法选择新疆医科大学第四临床医学院2022年3月至2023年1月的130例晚期NSCLC...目的探讨益气消癥汤治疗晚期非小细胞肺癌(Non-small-cell carcinoma,NSCLC)合并慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)的临床疗效。方法选择新疆医科大学第四临床医学院2022年3月至2023年1月的130例晚期NSCLC合并COPD患者,按随机数字表法分为对照组和观察组,各65例。对照组接受常规治疗,观察组在对照组常规治疗基础上加用益气消癥汤治疗,比较两组患者治疗前后肺功能水平、治疗效果、免疫功能以及不良反应。结果治疗3个月后,观察组患者一氧化碳弥散量(Diffusing capacity of the lungs for carbon monoxide,DLCO)、第一秒用力呼气容积(Forced expiratory volume in one second,FEV1)、FEV1/用力肺活量(Forced vital capacity,FVC)等肺功能指标均较对照组提高(P<0.05),且总体有效率高于对照组,差异有统计学意义(P<0.05)。观察组的免疫球蛋白含量和T细胞亚群水平均高于对照组(P<0.05),不良反应发生率低于对照组(P<0.05)。结论益气消癥汤在改善晚期NSCLC合并COPD患者肺功能、提升治疗效果、增强免疫功能方面优势明显,且不良反应小,临床应用安全可靠。展开更多
文摘Background: The purpose of this study is to evaluate the clinical efficacy and safety of abraxane-based chemotherapy with/without nedaplatin in elderly patients with non-small-cell lung cancer (NSCLC). Materials and methods: From October 2009 to January 2013, 48 elderly patients (≥65 years) with NSCLC were investigated in this clinical trial. The patients were randomized and equally allocated into arms A and AP- (A) abraxane (130 mg/m2, days 1, 8); (B) abraxane + nedaplatin (20 mg/m2 days 1-3, q3w). The parameters of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and side effects were evaluated between two arms. Results: Over 80% of the patients completed four cycles of chemotherapy. The total ORR was 21.3 %, DCR was 55.3%, PFS 4.5 months and OS 12.6 months. No significant difference was found between arms A and AP in terms of ORR (16.7% vs. 26.1%, P=0.665) or DCR (55.3% vs. 56.5%, P=0.871). The median PFS in arm A was 3.3 months [25-75% confidence interval (CI): 3.1-7.2] and 5.5 months (25-75% CI: 3.2-7.0) in arm AP with no statistical significance (P=0.640). The median OS in arm A was 12.6 months (25-75% CI: 5.7-26.2) and 15.1 months (25-75% CI: 6.4-35.3) in arm AP with no statistical significance (P=0.770). The side effects were mainly grade 1-2. The incidence of grade 3-4 toxicities was 29.1% in arm A and 62.5% in arm AP with a statistical significance (P=0.020). Conclusions: Compared with combined therapy, abraxane alone chemotherapy was beneficial for elderly NSCLC patients with better tolerability and less adverse events, whereas did not significantly differ in terms of ORR, DCR, PFS or OS.
文摘目的探讨益气消癥汤治疗晚期非小细胞肺癌(Non-small-cell carcinoma,NSCLC)合并慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)的临床疗效。方法选择新疆医科大学第四临床医学院2022年3月至2023年1月的130例晚期NSCLC合并COPD患者,按随机数字表法分为对照组和观察组,各65例。对照组接受常规治疗,观察组在对照组常规治疗基础上加用益气消癥汤治疗,比较两组患者治疗前后肺功能水平、治疗效果、免疫功能以及不良反应。结果治疗3个月后,观察组患者一氧化碳弥散量(Diffusing capacity of the lungs for carbon monoxide,DLCO)、第一秒用力呼气容积(Forced expiratory volume in one second,FEV1)、FEV1/用力肺活量(Forced vital capacity,FVC)等肺功能指标均较对照组提高(P<0.05),且总体有效率高于对照组,差异有统计学意义(P<0.05)。观察组的免疫球蛋白含量和T细胞亚群水平均高于对照组(P<0.05),不良反应发生率低于对照组(P<0.05)。结论益气消癥汤在改善晚期NSCLC合并COPD患者肺功能、提升治疗效果、增强免疫功能方面优势明显,且不良反应小,临床应用安全可靠。